Results 101 to 110 of about 15,238,642 (306)

Application progress on immunotherapy with chimeric antigen receptor T cell in patients with hematological malignancies

Huli yanjiu, 2020
Reviewing application progress on immunotherapy with chimeric antigen receptor T cell（CAR⁃T） in patients with hematological malignancies from 4 aspects,such as collection,pretreatment,note on cell reinfusion,and treatment complication of chimeric antigen
MENG Rui, XU Li, WAN Ying
doaj  

Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS prodigy system

, 2018
Wei Zhang,1 Kimberly R Jordan,2 Brian Schulte,3 Enkhtsetseg Purev1 1Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 2Division of Immunology, Department of Medicine, University of Colorado ...
Zhang W, Schulte B, Purev E, Jordan KR
core  

The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells [PDF]

, 2012
This article is available open access under a Creative Commons license (http://creativecommons.org/licenses/by-nc-nd/3.0/). Copyright @ 2012 Elsevier Inc.Lymphocytes provide optimal responses against pathogens with minimal inflammatory pathology. However,
Miao, T, Bhullar, P, Ghaffari, Emma, Liu, Mengya, Liu, M, Wang, Ping, Miao, Tizong, Li, Suling, Wang, P, Sebastian, M, Ghaffari, E, Sebastian, Meera, Symonds, Alistair L.J., Li, S, Symonds, ALJ, Bhullar, Punamdip   +15 more
core   +1 more source

Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis

Advanced Science, EarlyView.
Engineered macrophages programmed in situ by LNP‐delivered IL‐6/4 fusion and LL37 mRNAs simultaneously dampen cytokine storm, promote M2‐like repair, and enhance direct bacterial killing in sepsis. This combinatorial strategy restores T cell and macrophage function, lowers organ bacterial burden, and improves survival, highlighting a precision, host ...
Tianyang Jie, Zheyu Zhang, Hao Zhang, Linke Bian, Penglong Zheng, Sijia Zhou, Minqi Wang, Mingyu Qu, Yufei Wang, Xinhua Qu, Bing Yue   +10 more
wiley   +1 more source

Recent advances in adoptive cell therapy for cancer immunotherapy

Frontiers in Immunology
Adoptive cell therapy (ACT), a key direction in tumor immunotherapy, has achieved remarkable progress in recent years. This paper systematically reviews the current status and future trends of ACT, covering lymphokine-activated killer cells (LAK), tumor ...
Jiameng Qian, Jiameng Qian, Yuhua Liu, Yuhua Liu   +3 more
doaj   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

Advanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng, Lei Zheng, Rongkun Tao, Sirui Zheng, Yanke Zhong, Yongxia Niu, Peng Zhang, Xiang Ma, Chen Yang, Min Zhang, Fuyu Duan, Jing Yang, Xuan Wei, Xiang Zhou, Zhenbiao Yang, Zhaoxi Sun, Qizhou Lian   +16 more
wiley   +1 more source

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report

Journal of Medical Case Reports
Background Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton’s tyrosine kinase inhibitors proving effective but not curative.
G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero   +7 more
doaj   +1 more source

Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead

Frontiers in Bioscience-Elite
Chimeric antigen receptor–engineered macrophages (CAR-Ms) are emerging as a transformative frontier in immunotherapy and represent a promising strategy for pancreatic cancer.
Palloma Porto Almeida, Leandro Martins de Freitas   +1 more
doaj   +1 more source

Chimeric antigen receptor T cell therapies for multiple myeloma

Journal of Hematology & Oncology, 2019
Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies.
Chao Wu, Lina Zhang, Qierra R. Brockman, Fenghuang Zhan, Lijuan Chen   +4 more
doaj   +1 more source

Disease-specific outcomes after chimeric antigen receptor T-cell therapy

, 2022
International audienceWe compared outcomes of patients with B-cell malignancies treated in clinical trials with the same CD19 chimeric antigen receptor (CAR) T-cells across different indications, including B-cell acute lymphoblastic leukaemia (B-ALL ...
Vic, Samuel, Lemoine, Jean, Houot, Roch
core   +1 more source